Diet and other health-related behaviors of individuals with impaired glucose tolerance, cardiovascular disease (CVD) or CVD risk: A global view from the NAVIGATOR study

Diet and other health-related behaviors of individuals with impaired glucose tolerance, cardiovascular disease (CVD) or CVD risk: A global view from the NAVIGATOR study

Bibliographic Details
Main Authors:	Bales, C, Haffner, S, Thomas, L, Sun, J, Yates, T, Huffman, K, Califf, R, Toumilehto, J, McMurray, J, Holman, R, Davies, M, Kraus, W
Format:	Conference item
Published:	2013

Similar Items

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
by: Yates, T, et al.
Published: (2014)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
by: Yates, T, et al.
Published: (2014)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
by: Califf, R, et al.
Published: (2008)

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
by: Krum, H, et al.
Published: (2010)

Association of Baseline Physical Activity by Pedometer Counts and Nutritional Behavior on Metabolic Syndrome in the NAVIGATOR Study
by: Huffman, K, et al.
Published: (2013)

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR.
by: Huffman, K, et al.
Published: (2014)

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR
by: Huffman, K, et al.
Published: (2014)

Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR
by: McMurray, J, et al.
Published: (2004)

Relations between Baseline Physical Activity by Pedometer Counts and Future Cardiovascular Events in the NAVIGATOR Study
by: Kraus, W, et al.
Published: (2012)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
by: Preiss, D, et al.
Published: (2012)

Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study.
by: Preiss, D, et al.
Published: (2014)

Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
by: Mcmurray, J, et al.
Published: (2011)

Association of non-alcoholic steatothepatitis with components of the metabolic syndrome in 43,509 patients screened for NAVIGATOR
by: Bethel, A, et al.
Published: (2005)

Change in levels of physical activity after diagnosis of type 2 diabetes: An observational analysis from the NAVIGATOR study
by: Preiss, D, et al.
Published: (2014)

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
by: Preiss, D, et al.
Published: (2013)

Prediabetes and the risk of diabetes.
by: McMurray, J, et al.
Published: (2012)

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
by: Latini, R, et al.
Published: (2013)

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
by: Currie, G, et al.
Published: (2017)

Absolute CVD risk, stratified by risk score, was 20% higher in primary care patients with CVD than in those without CVD.
by: Lancaster, T
Published: (2009)

Evaluating Cardiovascular Disease (CVD) risk scores for participants with known CVD and non-CVD in a multiracial/ethnic Caribbean sample
by: Amalia Hosein, et al.
Published: (2020-03-01)

Education and Control of Risk Factors for Cardiovascular Disease (CVD) in Elderly Patients with CVD in Amirkola
by: A Hassanpour Jojadeh, et al.
Published: (2022-03-01)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
by: Califf, R, et al.
Published: (2003)

Silver transport in CVD silicon carbide
by: MacLean, Heather J. (Heather Jean), 1974-
Published: (2005)

ACP Journal Club. Absolute CVD risk, stratified by risk score, was 20% higher in primary care patients with CVD than in those without CVD.
by: Lancaster, T
Published: (2009)

Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study
by: Shen, L, et al.
Published: (2012)

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.
by: McMurray, J, et al.
Published: (2012)

Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial.
by: de Barros e Silva, P, et al.
Published: (2014)

Paramagnetic defects in CVD diamonds
by: Talbot-Ponsonby, D, et al.
Published: (1997)

Graphene grown by thermal CVD
by: Shanavas, Nitin.
Published: (2012)

Impact of CVD knowledge, risk perception, and barriers to healthcare on routine CVD management in Coimbatore, India
by: I. Balachandran, et al.
Published: (2015-03-01)

The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 x 2 factorial understanding risk trial.
by: Price, H, et al.
Published: (2008)

Target and Cell Therapy for Atherosclerosis and CVD
by: Yuliya V. Markina, et al.
Published: (2023-06-01)

Electrochemically controlled modification of CVD diamond surfaces
by: Foord, J, et al.
Published: (2004)

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
by: Shen, L, et al.
Published: (2013)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk
by: Bethel, M, et al.
Published: (2013)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.
by: Bethel, M, et al.
Published: (2013)

The effect of hydrogen on the electronic properties of CVD diamond films
by: Looi, H, et al.
Published: (1999)

Interaction of organo-sulfur compounds with CVD diamond surfaces
by: Baral, B, et al.
Published: (2000)

Knowledge of risk factors for diabetes or cardiovascular disease (CVD) is poor among individuals with risk factors for CVD.
by: Monique F Kilkenny, et al.
Published: (2017-01-01)

Characterisation of conductive CVD carbon-glass fibres
by: Alcaniz-Monge, J, et al.
Published: (2004)